TY - JOUR
T1 - The effects of blueberry and cranberry supplementation on blood pressure in patients with cardiovascular diseases
T2 - A systematic review and meta-analysis of randomized clinical trials
AU - Delpino, Felipe Mendes
AU - dos Santos, Francine Silva
AU - Flores, Thaynã Ramos
AU - Cerqueira, Henrique S.
AU - Santos, Heitor O.
N1 - Felipe Mendes Delpino received a doctoral scholarship from the National Council for Scientific and Technological Development (CNPq) during the preparation of the manuscript.
PY - 2024/2
Y1 - 2024/2
N2 - Blueberries and cranberries are berry fruits with the highest number of randomized clinical trials (RCTs) focusing on blood pressure (BP). This systematic review and meta-analysis of RCTs analyzed the effects of blueberry and cranberry supplementation alone and in concert with systolic BP (SBP) and diastolic BP (DBP) in patients with cardiometabolic diseases. The searches were performed until August 2023 in the following databases: PubMed, Scopus, Web of Science, Cochrane, and Embase. Studies that examined the effects of blueberry or cranberry intake/supplementation were included. The risk of bias was evaluated using the Rob 2 scale. A meta-analysis was performed to estimate the effects of blueberry and cranberry supplementation on BP levels in patients with cardiometabolic diseases. A total of 17 articles were included, from which two found significant results from blueberry and/or cranberry supplementation in reducing BP. Pooled results revealed statistically non-significant reductions of −0.81 mm Hg for SBP (95% confidence interval [CI]: −2.26, 0.63; I2 = 0%) and −0.15 mm Hg for DBP (95% CI: −1.36, 1.05; I2 = 27%). Blueberry and/or cranberry supplementation had neutral effects on SBP and DBP in patients with cardiometabolic diseases, regardless of duration or age. Further high-quality studies are needed to firmly establish clinical efficacy.
AB - Blueberries and cranberries are berry fruits with the highest number of randomized clinical trials (RCTs) focusing on blood pressure (BP). This systematic review and meta-analysis of RCTs analyzed the effects of blueberry and cranberry supplementation alone and in concert with systolic BP (SBP) and diastolic BP (DBP) in patients with cardiometabolic diseases. The searches were performed until August 2023 in the following databases: PubMed, Scopus, Web of Science, Cochrane, and Embase. Studies that examined the effects of blueberry or cranberry intake/supplementation were included. The risk of bias was evaluated using the Rob 2 scale. A meta-analysis was performed to estimate the effects of blueberry and cranberry supplementation on BP levels in patients with cardiometabolic diseases. A total of 17 articles were included, from which two found significant results from blueberry and/or cranberry supplementation in reducing BP. Pooled results revealed statistically non-significant reductions of −0.81 mm Hg for SBP (95% confidence interval [CI]: −2.26, 0.63; I2 = 0%) and −0.15 mm Hg for DBP (95% CI: −1.36, 1.05; I2 = 27%). Blueberry and/or cranberry supplementation had neutral effects on SBP and DBP in patients with cardiometabolic diseases, regardless of duration or age. Further high-quality studies are needed to firmly establish clinical efficacy.
KW - blood pressure
KW - blueberry
KW - cardiovascular disease
KW - cranberry
KW - hypertension
UR - http://www.scopus.com/inward/record.url?scp=85176958255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176958255&partnerID=8YFLogxK
U2 - 10.1002/ptr.8069
DO - 10.1002/ptr.8069
M3 - Review article
C2 - 37963472
AN - SCOPUS:85176958255
SN - 0951-418X
VL - 38
SP - 646
EP - 661
JO - Phytotherapy Research
JF - Phytotherapy Research
IS - 2
ER -